Immunic's (IMUX) "Buy" Rating Reaffirmed at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Immunic (NASDAQ:IMUX - Free Report) in a research report released on Thursday morning,Benzinga reports. D. Boral Capital currently has a $10.00 price objective on the stock.

IMUX has been the topic of several other research reports. William Blair reaffirmed an "outperform" rating on shares of Immunic in a research note on Friday, May 16th. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price objective on shares of Immunic in a research report on Thursday, May 1st. B. Riley reaffirmed a "buy" rating and set a $5.00 price objective (down previously from $6.00) on shares of Immunic in a report on Friday, May 23rd. Finally, Wall Street Zen cut shares of Immunic from a "hold" rating to a "sell" rating in a research note on Thursday, March 20th. One investment analyst has rated the stock with a sell rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $11.60.

Immunic Stock Performance

Shares of IMUX stock traded up $0.02 on Thursday, reaching $0.79. 2,456,208 shares of the company were exchanged, compared to its average volume of 858,636. Immunic has a 1 year low of $0.56 and a 1 year high of $2.11. The business has a 50-day moving average price of $0.97 and a 200 day moving average price of $1.05. The company has a market cap of $75.54 million, a price-to-earnings ratio of -0.64 and a beta of 1.73.

Immunic (NASDAQ:IMUX - Get Free Report) last posted its quarterly earnings results on Thursday, May 15th. The company reported ($0.25) earnings per share for the quarter, hitting the consensus estimate of ($0.25). As a group, equities analysts anticipate that Immunic will post -0.94 earnings per share for the current year.

Institutional Trading of Immunic

Institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC lifted its stake in shares of Immunic by 45.6% during the fourth quarter. Renaissance Technologies LLC now owns 566,623 shares of the company's stock valued at $567,000 after buying an additional 177,542 shares during the period. Barclays PLC acquired a new stake in Immunic during the 4th quarter valued at $84,000. Invesco Ltd. purchased a new position in Immunic in the fourth quarter valued at about $37,000. Focus Partners Wealth boosted its stake in Immunic by 1.1% during the 4th quarter. Focus Partners Wealth now owns 2,168,353 shares of the company's stock valued at $2,168,000 after acquiring an additional 23,610 shares during the last quarter. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Immunic by 90.0% in the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 204,579 shares of the company's stock worth $205,000 after purchasing an additional 96,894 shares in the last quarter. 51.82% of the stock is currently owned by hedge funds and other institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.